Actively Recruiting
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Daily Subcutaneous MANP in Adults with Resistant Hypertension
Led by E-Star BioTech, LLC · Updated on 2026-09-23
120
Participants Needed
23
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of MANP, a modified atrial natriuretic peptide, for people with difficult to control or resistant hypertension. This Phase 2, randomized, double-blind, placebo-controlled study aims to see if daily subcutaneous injections of MANP can reduce daytime systolic blood pressure measured by 24-hour ambulatory monitoring in patients taking three or more blood pressure medications. Participants will be randomly assigned to receive either MANP or a placebo once daily for 42 days. The study includes a dose titration process to find the appropriate dose. The placebo is a matched vehicle without the active drug. This trial is conducted at multiple centers and uses a quadruple-blind design to ensure unbiased results. During the study, participants will have their blood pressure monitored regularly, including 24-hour ambulatory blood pressure monitoring and clinic sitting blood pressure readings. Safety will be assessed by tracking adverse events and serious adverse events for up to 10 weeks, including 4 weeks after treatment ends. Blood samples will be taken to study drug levels and immune responses. The total participation time is about 10 weeks with regular visits for monitoring and assessments.
CONDITIONS
Brief Title
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Research Team
S
Seetha R Iyer, MS
L
Lucia Gonzalez
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here